Skip to main content
SpringerLink
Log in

B-cell Directed Therapy

  • Chapter
  • First Online:
Biologics for the Treatment of Rheumatoid Arthritis

  • 1058 Accesses

Abstract

Appreciation of the role of B-lymphocytes in the pathogenesis of rheumatoid arthritis (RA) has gone through various cycles. The discovery of rheumatoid factors as a specific marker for the disease pointed to a possible role for humoral (antibody-mediated) immunity and this was further strengthened by the discovery of anti-citrullinated peptide antibodies (ACPAs) many decades later.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273-281.

    Google Scholar 

  2. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-163.

    Google Scholar 

  3. Edwards JCW, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999;97:188-196.

    Google Scholar 

  4. Edwards JCW. Experience as a property of individual cells. https://www.ucl.ac.uk/jonathanedwards. Accessed October 12, 2015.

    Google Scholar 

  5. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40:205-211.

    Google Scholar 

  6. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCAassociated vasculitis. N Engl J Med. 2010;363:221-232.

    Google Scholar 

  7. Geetha D, Specks U, Stone JH, et al. Rituximab Versus Cyclophosphamide for ANCAAssociated Vasculitis with Renal Involvement. J Am Soc Nephrol. 2014 [Epub ahead of print]; doi:10.1681/ASN.2014010046.

    Google Scholar 

  8. Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56:1263-1272.

    Google Scholar 

  9. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64:1270-1272.

    Google Scholar 

  10. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.

    Google Scholar 

  11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-1400.

    Google Scholar 

  12. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-2806.

    Google Scholar 

  13. Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69:1158-1161.

    Google Scholar 

  14. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46.

    Google Scholar 

  15. van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558-567.

    Google Scholar 

  16. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68:1156-1164.

    Google Scholar 

  17. Arkema EV, van Vollenhoven RF, Askling J. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71:1865-1867.

    Google Scholar 

  18. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374-377.

    Google Scholar 

  19. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629-1635.

    Google Scholar 

  20. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-1693.

    Google Scholar 

  21. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:2652-2661.

    Google Scholar 

  22. Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eightweek randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012;64:350-359.

    Google Scholar 

  23. Emery P, Rigby W, Tak PP, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014;9:e87379.

    Google Scholar 

  24. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebocontrolled, phase I/II study. Arthritis Rheum. 2010;62:2227-2238.

    Google Scholar 

  25. Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis. 2011;70:2119-2125.

    Google Scholar 

  26. Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol. 2013;40:1089-1096.

    Google Scholar 

  27. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183-190.

    Google Scholar 

  28. Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, doseranging Study. J Rheumatol. 2013;40:579-589.

    Google Scholar 

  29. Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2013;65:880-889.

    Google Scholar 

  30. Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013;72:1461-1468.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit for Clinical Therapy Research, Karolinska University Hospital, Stockholm, Sweden

    Ronald F. van Vollenhoven

Authors
  1. Ronald F. van Vollenhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald F. van Vollenhoven .

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

van Vollenhoven, R.F. (2016). B-cell Directed Therapy. In: Biologics for the Treatment of Rheumatoid Arthritis. Adis, Cham. https://doi.org/10.1007/978-3-319-13108-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13108-5_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-13107-8

  • Online ISBN: 978-3-319-13108-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation